Photocure ASA: Results for the third quarter of 2026

Photocure posts modest revenue growth but faces declining profitability and leans on future pipeline.

What the company is saying

Photocure emphasizes its Q3 2026 financial results, highlighting Hexvix®/Cysview® revenues of NOK 134.2 million, nearly flat year-over-year, and total revenues of NOK 140.9 million, up from NOK 135.0 million. The company raises its 2026 product revenue growth guidance to 10–12% (from 8–11%) and signals anticipated adjusted EBITDA margin expansion. Operational progress is showcased through 13 new Saphira tower installations in the U.S. and a 20% increase in active U.S. accounts to 454, as well as 87 new Olympus Visera Elite III BLC system installations and 29 upgrades in Europe. Photocure frames its narrative around building a comprehensive bladder cancer diagnostics platform, combining established products with new molecular diagnostics, AI initiatives, and registry data. The appointment of Dennis Camporeale as CFO is positioned as a move to strengthen financial management. The company highlights the U.S. FDA’s proposed reclassification of BLC systems as a potential catalyst for broader adoption. Forward-looking statements focus on the expected launch and reimbursement of AssureMDx in 2027 and ongoing AI collaborations, but these are presented as ambitions rather than realised outcomes.

What the data suggests

The reported Hexvix®/Cysview® revenues for Q3 2026 were NOK 134.2 million, nearly unchanged from NOK 134.1 million a year earlier, while total revenues rose to NOK 140.9 million from NOK 135.0 million. Adjusted EBITDA declined slightly to NOK 18.5 million from NOK 18.9 million, and reported EBITDA fell more sharply to NOK 4.0 million from NOK 10.2 million. EBIT swung negative at NOK -3.4 million compared to NOK 2.9 million in Q3 2025. Cash and cash equivalents stood at NOK 162.4 million at quarter-end. Operationally, U.S. account growth was strong at 20% year-over-year, and system installations expanded in both the U.S. and Europe. The company’s updated guidance for 2026 product revenue growth (10–12%) is more optimistic than before, but margin expansion remains an expectation, not a demonstrated trend. Claims of cost neutrality and clinical impact are not supported by disclosed data. Pipeline initiatives, including AssureMDx and AI-enabled diagnostics, are in development, with initial AssureMDx revenue and reimbursement targeted for 2027, but no current financial contribution from these is evident.

Analysis

The announcement presents a positive tone, highlighting revenue growth guidance, operational expansion, and new product initiatives. Realised financial and operational data are disclosed for Q3 2026, including revenues, EBITDA, EBIT, cash, and installation metrics, supporting claims of commercial progress. However, profitability metrics (reported EBITDA and EBIT) declined year-over-year, and margin expansion is only anticipated, not demonstrated. Several forward-looking statements—such as AssureMDx revenue and reimbursement (expected in 2027), AI-enabled technology, and broader platform ambitions—are aspirational and lack supporting quantitative evidence or timelines for impact. The claim of cost neutrality is not substantiated with data. While the company is not disclosing a large capital outlay with long-dated returns, the narrative inflates the significance of pipeline and registry developments relative to current financial performance. The gap between narrative and evidence is moderate, with over half of key claims being forward-looking.

Risk flags

• ●Profitability is under pressure, with reported EBITDA dropping from NOK 10.2 million to NOK 4.0 million and EBIT turning negative at NOK -3.4 million. Sustained margin compression could limit reinvestment capacity and dampen investor confidence if not reversed.
• ●A significant portion of the growth narrative relies on pipeline products and regulatory changes, such as AssureMDx and the FDA’s proposed BLC system reclassification. Delays or setbacks in these areas could undermine future revenue and market expansion.
• ●The company’s claims of clinical and economic value, including cost neutrality and improved patient outcomes, are not substantiated by disclosed data. This lack of transparency on outcomes introduces uncertainty about the real-world impact and adoption of its technologies.
• ●Cash reserves of NOK 162.4 million provide a buffer, but ongoing investment in new initiatives and the absence of near-term profitability improvements could erode this position if revenue growth does not materialize as projected.
• ●Leadership transition with the appointment of a new CFO introduces some execution risk, particularly as the company pursues a more ambitious growth and diversification strategy.

Bottom line

Photocure’s Q3 2026 results show stable product revenues and solid operational expansion, especially in the U.S., but profitability is weakening, with reported EBITDA and EBIT both declining year-over-year. The company is raising its 2026 product revenue growth guidance and investing in new diagnostic and AI initiatives, but these pipeline projects are not yet contributing financially and are at least several quarters from generating revenue. The FDA’s proposed regulatory change could be a catalyst, but its timing and impact remain uncertain. Management’s narrative is forward-leaning, with many claims about future value not yet backed by data. Investors should focus on whether margin expansion and pipeline monetization materialize in 2027 as forecast. The most important takeaway is that near-term growth is incremental, while the bulk of the upside depends on successful execution and realization of longer-term pipeline ambitions.

Announcement summary

(OSE: PHO) Photocure ASA reported Hexvix® /Cysview® revenues of NOK 134.2 million in the third quarter of 2026, compared to NOK 134.1 million in Q3 2025. Adjusted EBITDA for Q3 2026 was NOK 18.5 million, versus NOK 18.9 million in Q3 2025. The company now expects product revenue growth in 2026 in the range of 10% to 12% on a constant currency basis, up from the previous guidance of 8% to 11%, and anticipates adjusted EBITDA margin expansion. In Q3 2026, Photocure installed 13 new Saphira towers in the United States, including 9 in new accounts and 4 upgrades. The number of active accounts in the U.S. reached 454 at the end of the quarter, representing a 20% increase compared to Q3 2025. In Europe, 87 Olympus Visera Elite III BLC capable systems have been installed since Q1 2025, along with 29 upgraded rigid systems year-to-date from Karl Storz, Richard Wolf, and Stryker. Total revenues for Q3 2026 were NOK 140.9 million, up from NOK 135.0 million in Q3 2025. Reported EBITDA was NOK 4.0 million, compared to NOK 10.2 million in the prior year period. EBIT was NOK -3.4 million, versus NOK 2.9 million in Q3 2025. Cash and cash equivalents stood at NOK 162.4 million at the end of the period. Dennis Camporeale was appointed as Chief Financial Officer, bringing experience in medtech and diagnostics investment banking, mergers and acquisitions, strategic advisory, business development, and corporate finance. The U.S. Food and Drug Administration published a proposal in August to reclassify applicable BLC systems from Class III to Class II, which would establish a new regulatory framework with special controls and a 510(k) pathway, subject to the FDA's final determination. Photocure continues to build clinical and economic evidence to support BLC adoption in the United States, with recent publications demonstrating cost neutrality between BLC and white light cystoscopy in the studied population and highlighting opportunities to improve prediction of bladder cancer recurrence and progression. The growing Cysview registry is providing a foundation for understanding patient outcomes and developing individualized disease management approaches. Following the acquisition of Vesica Health, AssureMDx is positioned as a second growth engine, offering a multi-omic, urine-based molecular test for risk stratification and evaluation of patients with hematuria. Initial AssureMDx revenue is expected in 2027, with reimbursement anticipated during the first half of 2027. Photocure is advancing AI-enabled technology for BLC procedures through collaboration with Claritas HealthTech and its subsidiary Intelligent Scopes Corporation, with the ENAiBLE trial now having recruited over 100 patients. The company is also collaborating with Artera to evaluate the ArteraAI Bladder Test, which remains under development, leveraging the Cysview registry for validation. For 2026, Photocure reiterates its expectation of 10% to 12% product revenue growth on a constant currency basis and continued adjusted EBITDA margin expansion. The company is focused on building a broader precision diagnostics platform in bladder cancer, combining early risk assessment, procedural detection, and data-enabled patient management.

Disagree with this article?